Compare Stocks: IMCC, ZYBT, TENX, and CING

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$5.44 +0.7%	$5.03	$3.16 ▼ $11.89	$78.53M	-0.9	154,216 shs	150,602 shs
IMCC IM Cannabis	$3.94 +17.9%	$4.04	$2.57 ▼ $78.36	$690K	2.07	3.28 million shs	203,262 shs
TENX Tenax Therapeutics	$2.19 +3.3%	$11.18	$1.31 ▼ $19.40	$79.34M	0.93	10.52 million shs	2.62 million shs
ZYBT Zhengye Biotechnology	$1.76 -3.8%	$1.42	$0.62 ▼ $13.08	$86.73M	-2.72	4.64 million shs	45,964 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	+0.74%	+2.06%	+20.09%	+30.77%	+30.14%
IMCC IM Cannabis	+17.89%	+15.10%	+20.71%	-54.40%	-94.21%
TENX Tenax Therapeutics	+3.30%	+23.03%	-86.14%	-81.55%	-63.01%
ZYBT Zhengye Biotechnology	-3.83%	-6.88%	+32.33%	+112.30%	-79.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$5.44 +0.7%	$5.03	$3.16 ▼ $11.89	$78.53M	-0.9	154,216 shs	150,602 shs
IMCC IM Cannabis	$3.94 +17.9%	$4.04	$2.57 ▼ $78.36	$690K	2.07	3.28 million shs	203,262 shs
TENX Tenax Therapeutics	$2.19 +3.3%	$11.18	$1.31 ▼ $19.40	$79.34M	0.93	10.52 million shs	2.62 million shs
ZYBT Zhengye Biotechnology	$1.76 -3.8%	$1.42	$0.62 ▼ $13.08	$86.73M	-2.72	4.64 million shs	45,964 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	+0.74%	+2.06%	+20.09%	+30.77%	+30.14%
IMCC IM Cannabis	+17.89%	+15.10%	+20.71%	-54.40%	-94.21%
TENX Tenax Therapeutics	+3.30%	+23.03%	-86.14%	-81.55%	-63.01%
ZYBT Zhengye Biotechnology	-3.83%	-6.88%	+32.33%	+112.30%	-79.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.50	Moderate Buy	$27.00	396.32% Upside
IMCC IM Cannabis	1.00	Sell	N/A	N/A
TENX Tenax Therapeutics	2.56	Moderate Buy	$14.00	539.27% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMCC, ZYBT, TENX, and CING Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$10.00 ➝ $9.00
8/18/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	TENX Tenax Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$35.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$40.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
8/11/2026	TENX Tenax Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/11/2026	TENX Tenax Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
8/10/2026	TENX Tenax Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	TENX Tenax Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$1.61 per share	N/A
IMCC IM Cannabis	$39.17M	0.63	N/A	N/A	($0.65) per share	-6.06
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$3.04 per share	N/A
ZYBT Zhengye Biotechnology	$116.36M	0.72	N/A	N/A	$0.93 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
IMCC IM Cannabis	-$8.10M	-$2.02	N/A	N/A	N/A	-39.62%	-585.96%	-58.32%	11/16/2026 (Estimated)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-61.54%	-57.42%	11/11/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IMCC, ZYBT, TENX, and CING Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A
8/13/2026	Q2 2026	IMCC IM Cannabis	N/A	-$0.34	N/A	-$9.92	N/A	$5.34 million
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	3.50	3.50
IMCC IM Cannabis	N/A	0.56	0.46
TENX Tenax Therapeutics	N/A	15.07	15.07
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
IMCC IM Cannabis	7.68%
TENX Tenax Therapeutics	1.67%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.30%
IMCC IM Cannabis	5.91%
TENX Tenax Therapeutics	10.81%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	20	14.54 million	13.77 million	Not Optionable
IMCC IM Cannabis	340	6.22 million	5.86 million	Not Optionable
TENX Tenax Therapeutics	9	37.42 million	33.38 million	Not Optionable
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

IMCC, ZYBT, TENX, and CING Headlines

Recent News About These Companies

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

February 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, ZYBT, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

$5.44 +0.04 (+0.74%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$5.42 -0.02 (-0.28%)

As of 07:18 AM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

IM Cannabis NASDAQ:IMCC

$3.94 +0.60 (+17.89%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$3.86 -0.07 (-1.90%)

As of 07:52 AM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Tenax Therapeutics NASDAQ:TENX

$2.19 +0.07 (+3.30%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$2.19 +0.00 (+0.23%)

As of 07:50 AM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Zhengye Biotechnology NASDAQ:ZYBT

$1.76 -0.07 (-3.83%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.05 (+2.61%)

As of 07:33 AM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCC, ZYBT, TENX, and CING Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCC, ZYBT, TENX, and CING Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCC, ZYBT, TENX, and CING Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, ZYBT, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

IM Cannabis NASDAQ:IMCC

Tenax Therapeutics NASDAQ:TENX

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCC, ZYBT, TENX, and CING Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCC, ZYBT, TENX, and CING Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCC, ZYBT, TENX, and CING Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, ZYBT, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

IM Cannabis NASDAQ:IMCC

Tenax Therapeutics NASDAQ:TENX

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools